|
|
|
|
|
|
|
|
|
|
medscape
American Society of Clinical Oncology (ASCO) 2016 Annual Meeting: Abstract LBA5503, presented June 5, 2016; Abstract 5504, presented June 3, 2016.
CHICAGO — Intraperitoneal (IP) chemotherapy is now an alternative to intravenous (IV) administration that "must be discussed" for women with cytoreduced ovarian cancer, several experts said here at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
But the phase 2 data that prompted those comments "will do nothing to settle the controversy" surrounding the choice of IP or IV therapy, Richard Schilsky, MD, ASCO chief medical officer, told Medscape Medical News.....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.